China-based InventisBio (Shanghai) has signed a 'Collaboration Agreement' with China-based Betta Pharma, it was reported on Friday.
According to the contract, InventisBio will out-license D-0316's right in China (including mainland China, Hong Kong and Taiwan) to Betta Pharma and is to co-develop this drug in China. Betta Pharma will have the exclusive commercialisation rights for the D-0316 product in the country.
The product is a third-generation EGFR-T790M tyrosine kinase inhibitor discovered and developed independently by InventisBio. It is mainly utilised for the treatment of EGFR-mutant non-small cell lung cancer. The drug is presently in phase one clinical trial in China. Betta Pharma will pay upfront and R&D milestones to InventisBio worth RMB230m. After the product is marketed commercially, Betta Pharma will pay various sales milestones and tiered royalties based on annual sales.
GSK reports positive Phase III data for low-carbon version of Ventolin inhaler
Merck reports long-term survival benefits of Keytruda in non-small cell lung cancer
Sanofi reports data showing high-dose flu vaccine delivers superior protection for older adults
AstraZeneca wins US FDA approval for Tezspire in chronic rhinosinusitis with nasal polyps
Sichuan Kelun-Biotech presents positive Phase 3 trial results for sac-TMT
SOPHiA DDM Digital Twins launched to simulate patient outcomes and support oncology decisions
Novocure announces presentation of new TTFields research at EANO and ESMO 2025 meetings
Mabwell to present latest 7MW3711 clinical results at 2025 ESMO Congress
Actinium Pharmaceuticals to reveal ATNM-400 data in NSCLC at AACR-NCI-EORTC International Conference